| Literature DB >> 27534937 |
Megan J Osmond-McLeod1,2,3, Yalchin Oytam4,5, Anthony Rowe5, Fariborz Sobhanmanesh5, Gavin Greenoak6, Jason Kirby4,7, Elizabeth F McInnes8, Maxine J McCall4,5.
Abstract
BACKGROUND: The application of sunscreen is a critical component of a sun-safe strategy, however the possibility of unexpected, adverse outcomes resulting from long-term use of sunscreens containing nanoparticles of titanium dioxide (TiO2) and zinc oxide (ZnO) has not yet been examined. Here, immune-competent hairless mice were exposed over a 36-week period to weekly topical applications of sunscreens containing nanoparticles of ZnO or TiO2, or no metal oxide nanoparticles, with or without subsequent exposure to ultraviolet radiation (UVR). Control groups received no sunscreen applications, with or without UVR.Entities:
Keywords: Long-term; Nanoparticles; Organic UV filter; Sunscreen; Ultraviolet radiation
Mesh:
Substances:
Year: 2016 PMID: 27534937 PMCID: PMC4989375 DOI: 10.1186/s12989-016-0154-4
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Treatment groups in Series 1 and Series 2
| Group ID | Treatment | |
|---|---|---|
| Series 1 | Control-UVR | No sunscreen, no UVR |
| Control + UVR | No sunscreen + 29 kJ/m2 UVR | |
| ZnO-UVR | ZnO sunscreen, no UVR | |
| ZnO + UVR | ZnO sunscreen + 29 kJ/m2 UVR | |
| TiO2-UVR | TiO2 sunscreen, no UVR | |
| TiO2 + UVR | TiO2 sunscreen + 29 kJ/m2 UVR | |
| Organic-UVR | Organic sunscreen, no UVR | |
| Organic + UVR | Organic sunscreen + 29 kJ/m2 UVR | |
| Series 2 | 2-Control-UVR | No sunscreen, no UVR |
| 2-Control + UVR | No sunscreen + 27 kJ/m2 UVR | |
| 2-ZnO-UVR | ZnO sunscreen, no UVR | |
| 2-ZnO + UVR | ZnO sunscreen + 27 kJ/m2 UVR |
Fig. 1a TEM images of ZnO and TiO2 particles extracted from their respective sunscreens. Scale bar = 100 nm; b Histogram showing the distribution of particle diameters. 233 and 257 measurements were made for ZnO and TiO2 particles, respectively
Histological findings for all treatment groups from Series 1 and Series 2
| Group ID | Sunscreen | UVR kJ/m2 | Number of mice per group | Number of mice that reached endpoint without AE | Total mice with AE | Mice with AE related to malignant or pre-malignant findings (histologically diagnosed) | Mice with AE related to non-malignant findings (histologically diagnosed) | Mice with AE, no necroscopy | Total mice at predetermined endpoint with malignant findings (histologically diagnosed) | Total mice at predetermined endpoint with non-malignant findings (histologically diagnosed) | Total mice at predetermined endpoint with no malignant or non-malignant findings | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series 1 | Control-UVR | None | 0 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| Control + UVR | None | 29 | 10 | 6 | 4 | 4 (1 X CFS; 1 X CFS + SCC; 1 X LL; 1 X SCP) | 0 | 0 | 1 (1 X SCP) | 4a | 1 | |
| ZnO-UVR | ZnO | 0 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 1 (1 X PA) | 9 | |
| ZnO + UVR | ZnO | 29 | 10 | 5 | 5 | 1 (1 X LL) | 2 (1 X N; 1 X HC) | 2 | 1 (1 X CFS) | 0 | 4 | |
| TiO2-UVR | TiO2 | 0 | 10 | 9 | 1 | 0 | 1 (1 X P) | 0 | 0 | 0 | 9 | |
| TiO2 + UVR | TiO2 | 29 | 10 | 10 | 0 | 0 | 0 | 0 | 2 (2 X BAC) | 1 (1 X PA) | 7 | |
| Organic-UVR | Organic | 0 | 10 | 9 | 1 | 1 (1 X LL) | 0 | 0 | 0 | 0 | 9 | |
| Organic + UVR | Organic | 29 | 10 | 9 | 1 | 0 | 0 | 1 | 1 (1 X LL) | 0 | 8 | |
| Series 2 | 2-Control-UVR | None | 0 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 10 |
| 2-Control + UVR | None | 27 | 10 | 9 | 1 | 1 (1 X LL) | 0 | 0 | 7 (1 X BAC; 4 X SCC; 1 X LL; 1 X CFS & SCP) | 0 | 2 | |
| 2-ZnO-UVR | ZnO | 0 | 10 | 9 | 1 | 1 (1 X LL) | 0 | 0 | 1 (1 X OS) | 0 | 8 | |
| 2-ZnO + UVR | ZnO | 27 | 10 | 9 | 1 | 0 | 1 (1 X E) | 0 | 0 | 0 | 9 |
The predetermined endpoint for both groups was 36 weeks
CODE: AE adverse event, BAC bronchioalveolar carcinoma, CFS cutaneous fibrosarcoma, E endometritis, HC haemolytic crisis, LL lymphocytic lymphoma, N nephropathy, OS osteosarcoma, P peritonitis, PA pulmonary adenoma, SCC squamous cell carcinoma, SCP squamous cell papilloma
aNo malignant or non-malignant outcomes, but moderate to severe dermal hyperplasia and inflammation were histologically diagnosed in all four mice
Fig. 2Images of representative histological skin sections from mice from Series 1 and 2 receiving: a no treatment; b weekly exposure to UVR with no sunscreen; c weekly exposure to UVR with pre-applications of sunscreen containing nanoparticles of ZnO as the only UV active ingredient; d weekly exposure to UVR with pre-application of sunscreen containing nanoparticles of TiO2 and organic UV active ingredients; e weekly exposure to UVR with pre-application of sunscreen containing only organic UV active ingredients. Images on the left were taken from mice in Series 1, and on the right in Series 2. The only treatment-specific effects were in the mice receiving UVR treatments with no sunscreen (Control + UVR), here represented by a squamous cell papilloma (SCP) in Series 1 (encompassed by a black bracket), and in Series 2 (i) a cutaneous fibrosarcoma (CFS) (black arrow indicates mitotic figure in fibrosarcoma) and (ii) squamous cell carcinoma (SCC) (black arrow indicates “keratin pearl” in SCC). The skin from all other treatment groups showed unremarkable epidermis and dermis
Mean concentrations of Zn in tissues (wet mass) from untreated mice, and treated mice receiving UVR only, or ZnO sunscreen (± UVR) in Series 1
| Group ID | Sunscreen | UVR (kJ/m2) | μg/kg | Mean μg/g ± SEM | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Skin | Brain | Liver | Spleen | Kidney | Lung | |||||
| Series 1 | Control-UVR | None | None | Zn | 14.5 ± 0.7 | 12.2 ± 0.8 | 19 ± 1 | 17.4 ± 0.5 | 14.8 ± 0.7 | 16.9 ± 0.5 |
| Control + UVR | None | 29 | Zn | 13 ± 2 | 15 ± 3 | 20 ± 1 | 17.6 ± 0.6 | 15.7 ± 0.8 | 16.6 ± 0.6 | |
| ZnO-UVR | ZnO | None | Zn | 82 ± 9a | 12.1 ± 0.6 | 21 ± 1 | 18.2 ± 0.1 | 16.6 ± 0.6 | 16.1 ± 0.4 | |
| ZnO + UVR | ZnO | 29 | Zn | 73 ± 10a | 13 ± 1 | 21 ± 1 | 17.3 ± 0.5 | 17.3 ± 0.7 | 16.4 ± 0.4 | |
The practical quantification limit of Zn was 0.4 μg/kg; n = 5 for all tissues in all groups except for Control + UVR Skin, for which n = 4
SEM Standard Error of the Mean
aSignificantly different from untreated mice (Control-UVR)
Fig. 3Mean concentrations of Ti in livers (dry mass) of untreated mice, and mice receiving TiO2 sunscreen (± UVR) in Series 1. *Significantly different from untreated mice (Control-UVR) (p < 0.001)
Fig. 4a VENN diagram showing the number of unique or shared transcripts within and between mice exposed to UVR, with (TiO2 + UVR, Organic + UVR) or without (Control + UVR) prior application of sunscreen. Numbers indicate differentially-expressed transcripts that were either unique to one treatment (unshared VENN), or differentially-expressed in more than one treatment (intersecting VENN); b VENN diagram showing the number of unique or shared transcripts within and between mice receiving topical applications of the organic sunscreen, with (Organic + UVR) or without (Organic-UVR) subsequent UVR exposure
Top 5 canonical transcriptional pathways perturbed in treated, relative to untreated, mice from Series 1
| Group ID | Sunscreen | UVR (kJ/m2) | Top 5 canonical pathways |
|---|---|---|---|
| Control + UVR | None | 29 | Role of BRCA1 in DNA Damage Response; Cholecystokinin/Gastrin-Mediated Signalling; ATM Signalling; NF-kB Signalling; DNA Double-Strand Break Repair by Non-Homologous End Joining |
| ZnO-UVR | ZnO | 0 | No statistically significant differentially expressed genes identified |
| ZnO + UVR | ZnO | 29 | No statistically significant differentially expressed genes identified |
| TiO2-UVR | TiO2 | 0 | No statistically significant differentially expressed genes identified |
| TiO2 + UVR | TiO2 | 29 | Circadian Rhythm Signalling; Tetrapyrrole Biosynthesis II; Heme Biosynthesis II; Breast Cancer Regulation by Stathmin1; Mevalonate Pathway I |
| Organic-UVR | Organic | 0 | Estrogen Receptor Signalling; UVA-induced MAPK Signalling; All-trans-decaprenyl Diphosphate Biosynthesis; Remodelling of Epithelial Adherens Junctions; Phosphatidylethanolamine Biosynthesis II |
| Organic + UVR | Organic | 29 | Protein Ubiquitination Pathway; tRNA Charging; Estrogen Receptor Signalling; Remodelling of Epithelial Adherens Junctions; EIF2 Signalling |
Active ingredients of sunscreens used in this study
| Sunscreen | Active ingredients |
|---|---|
| ZnO | ZnO (200 mg/g) |
| TiO2 | TiO2 (40 mg/mL) |
| OCM (70 mg/mL) | |
| B-MDM (40 mg/mL) | |
| Organic | OCM (99 mg/mL) |
| B-MBM (19.8 mg/mL) | |
| 4-MBC (37.6 mg/mL) | |
| Octocrylene (9.9 mg/mL) |